Introduction {#Sec1}
============

Breast cancer incidence has increased substantially over the last decades \[[@CR1], [@CR2]\], which, in combination with improved survival rates attributable to the availability of screening methods and effective treatments of early and more advance breast cancer \[[@CR3], [@CR4]\], leads to an increasing number of breast cancer survivors. Cardiovascular disease (CVD) is an important cause of death among these women as the risk of CVD may be increased by cardiotoxic treatments and CVD risk factors \[[@CR5]--[@CR8]\].

The risk of (death from) CVD following breast cancer is increased in women exposed to cardiotoxic treatments such as mediastinal and left-sided radiotherapy, anthracycline-based chemotherapy, and trastuzumab, and is even higher in patients with pre-existing CVD risk factors such as diabetes and hypertension \[[@CR9]--[@CR12]\]. With the current high breast cancer survival rates, especially for women with lower stages, and the large number of women with breast cancer receiving intensive treatment regimens, it is increasingly important to identify patients at high risk of CVD, and to balance the benefits of breast cancer treatment for achieving tumor control with the risks of cardiac toxicity inducing CVD.

As an overview of the available evidence on the risk of dying of CVD in women with breast cancer is currently lacking, we systematically reviewed the literature on the risk and risk factors of death from CVD following breast cancer.

Methods and materials {#Sec2}
=====================

This systematic review was conducted in accordance with the Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR13]\].

A systematic search was performed, and last updated on April 1, 2017, to identify all studies reporting on the risk and risk factors of death from CVD following breast cancer. Databases of Medline (via PubMed), Embase, and the Cochrane Library were systematically searched using the following terms and their synonyms in the search strategy: breast cancer, cardiovascular disease, and cause of death (Table [1](#Tab1){ref-type="table"}). No limits were used.Table 1Search strategy performed in Medline (via Pubmed)Search strategy (Medline via Pubmed)\#1(Breast Neoplasms\[Mesh Terms\] OR cancer\[Title/Abstract\] OR cancers\[Title/Abstract\] OR carcinoma\[Title/Abstract\] OR carcinomas\[Title/Abstract\] OR tumor\[Title/Abstract\] OR tumors\[Title/Abstract\] OR tumor\[Title/Abstract\] OR tumors\[Title/Abstract\] OR malignancy\[Title/Abstract\] OR malignancies\[Title/Abstract\] OR neoplasm\[Title/Abstract\] OR neoplasms\[Title/Abstract\] OR neoplasms\[Mesh Terms\]) AND (breast\[Title/Abstract\] OR breasts\[Title/Abstract\] OR mamma\[Title/Abstract\] OR mamma\*\[Title/Abstract\])\#2(Cardiovascular Diseases\[Mesh\] OR heart\[Title/Abstract\] OR cardiac\[Title/Abstract\] OR cardio\[Title/Abstract\] OR cardiovascular\[Title/Abstract\] OR coronary\[Title/Abstract\] OR ventricular\[Title/Abstract\] OR valvular\[Title/Abstract\] OR circulatory\[Title/Abstract\]) AND (disease\[Title/Abstract\] OR diseases\[Title/Abstract\] OR complication\[Title/Abstract\] OR complications\[Title/Abstract\] OR failure\[Title/Abstract\] OR failures\[Title/Abstract\] OR dysfunction\[Title/Abstract\] OR dysfunctions\[Title/Abstract\] OR mortality\[Title/Abstract\] OR mortalities\[Title/Abstract\] OR death\[Title/Abstract\] OR deaths\[Title/Abstract\] OR arrhythmias\[Title/Abstract\] OR arrhythmia\[Title/Abstract\] OR cardiomyopathy\[Title/Abstract\] OR cardiomyopathies\[Title/Abstract\] OR Ischemia\[Title/Abstract\] OR Ischemia's\[Title/Abstract\] OR all\[Title/Abstract\]) AND (cause\[Title/Abstract\] or causes\[Title/Abstract\] OR other\[Title/Abstract\])\#3(Cause of death\[Mesh Terms\] OR mortality\[Title/Abstract\] OR mortalities\[Title/Abstract\] OR death\[Title/Abstract\] OR deaths\[Title/Abstract\] OR fatality\[Title/Abstract\] OR fatalities\[Title/Abstract\] OR dying\[Title/Abstract\])\#4\#1 AND \#2 AND \#3Comparable search strategies have been conducted for Embase and the Cochrane Library

Articles reporting on both risk and risk factors of CVD mortality in breast cancer patients were eligible for inclusion. Articles with the following criteria were excluded: (1) published before 1990, (2) written in another language than English or Dutch, (3) case reports, reviews, or abstracts. Cross-referencing was performed.

Selection of studies and data extraction {#Sec3}
----------------------------------------

After removal of duplicates, all titles and abstracts of the remained retrieved articles were screened. Abstracts that seemed potentially relevant, based on the in- and exclusion criteria, were screened for full text. The full text of these articles were assessed for eligibility by three investigators independently (S.A.M. Gernaat, P.J. Ho, and N. Rijnberg). Data were extracted using standardized data extraction forms and any disagreements were resolved by discussion. We extracted data on study size, characteristics of breast cancer patients (age, ethnic origin, year of diagnosis, years of follow-up), study design, International Classification of Diseases (ICD) codes for CVD mortality, absolute risk of death from CVD, absolute risk of death from breast cancer, absolute risk of death from any cause, statistical methods used to assess which factors increase the risk of death from CVD, and the risk of CVD mortality per risk factor.

Quality assessment {#Sec4}
------------------

The methodological quality for each article was assessed by two authors independently (S.A.M. Gernaat and P.J. Ho) using the Newcastle Ottawa Quality Assessment Scale (NOS) for cohort studies \[[@CR14]\]. The NOS consists of six multiple-choice questions that address subject selection, comparability, and the assessment of the outcome (i.e. CVD mortality), which sum up to a maximum score of seven. In the present study, a high score on one of these sections indicated that the maximum score (i.e. two for selection and comparability, and three for outcome) was achieved. In all other cases, the study received a low score on that particular section.

Results {#Sec5}
=======

The systematic search yielded 10,170 citations including 5911 unique articles, which were screened for title and abstract using the predefined inclusion and exclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). After screening the full text of 39 articles, 27 were excluded for the following reasons: published before the calendar year 1990 (*n* = 3) or articles that did not report the risk and risk factors of death from CVD (*n* = 24). Cross-referencing identified two additional papers. In total, 14 articles were included in the current systematic review, including 4,773,576 women of which 1,217,910 were diagnosed with breast cancer \[[@CR5], [@CR6], [@CR8], [@CR15]--[@CR25]\].Fig. 1Flowchart of the systematic review on the risk of death from cardiovascular disease in breast cancer patients

Quality assessment {#Sec6}
------------------

The majority of the studies had the maximum score on the quality assessment for selection, comparability, and outcome \[[@CR5], [@CR8], [@CR17], [@CR18], [@CR20]--[@CR22], [@CR26]\] (Fig. [2](#Fig2){ref-type="fig"}). The study by Nichols et al. \[[@CR15]\] had a low score on selection as the study population was a selected group of in situ or invasive breast cancer patients and breast cancer ascertainment was by written self-report. The studies by Berkman et al. \[[@CR6]\], Darby et al. \[[@CR23]\], and Giordano et al. \[[@CR24]\] had low scores on comparability as the hazard ratios (HRs) were not adjusted for factors other than age at diagnosis, the CVD mortality rates were unadjusted, and the HRs were only adjusted for other factors than age at diagnosis, respectively. The studies by Hooning et al. \[[@CR25]\] and McCullough et al. \[[@CR16]\] had low scores on the outcome attainment as the assessment of CVD deaths was by hospital records and subjects were lost to follow-up or the follow-up rate was less than 70%, respectively.Fig. 2Quality assessment by the Newcastle Ottawa Quality Assessment Scale Selection was based on the representativeness of the breast cancer cohort and ascertainment of breast cancer. Comparability was based on the comparability of cohorts on the basis of the design or analysis. Outcome was based on the assessment of death from cardiovascular disease, on the length of follow-up (≥10 years), and adequacy of follow-up of the cohorts. A high score on one of these sections indicated that the maximum score on that particular section (i.e. two for selection and comparability, and three for outcome) was achieved. In all other cases, the study received a low score on that particular section

Cardiovascular disease mortality in breast cancer patients compared with the general population {#Sec7}
-----------------------------------------------------------------------------------------------

Bradshaw et al. \[[@CR8]\] included 1413 women with primary in situ or invasive breast cancer diagnosed in the United States (U.S.) between 1996 and 1997, and 1411 age-matched women from the general population (Table [2](#Tab2){ref-type="table"}). Mean age at breast cancer diagnosis and reference date for women from the general population were 59 and 57 years, respectively. During the follow-up time, which ranged between 0.2 and 13.5 years for both groups, 9.4% of women with breast cancer and 7.4% of women from the general population died of CVD. After adjusting for age, menopausal status, and other CVD risk factors, women with breast cancer had a 1.9 (95% confidence interval (CI) = 1.4--2.7) times higher risk to die of CVD after at least 7 years post diagnosis than women from the general population (Table [3](#Tab3){ref-type="table"}).Table 2Characteristics and risk of cardiovascular disease mortality of the fourteen articles included in the systematic reviewFirst author, publication year, countryType of breast cancer, number of patientsAge at diagnosis or reference date, yYear of diagnosis, years of follow-upICD-9 and/or ICD-10 codes of CVD mortality outcomesPercentage of deaths due to any cause, CVD, and BC (percentage of total)CVD mortality in breast cancer patients compared with the general populationBradshaw, 2016, US^a^Primary in situ or invasive; 141359 or 57^d^1996--1997, 13.5^e^ICD-9: 394.9, 402.9, 410, 414.0, 427.5*Women with BCWomen without BC*Any cause: 29.4Any cause: 17.2ICD-10: I10, I11.9, I21.9, I25.1, I25.4, I46.9Without BC; 1411^c^CVD: 9.4\
BC: 9.6CVD: 7.4\
BC: 0.1Riihimäki, 2012, Sweden^a^Primary invasive; 122,217--1987--2006, 19^e^ICD-9: 410, 411--414, 420--427, 428, 430--438, 440--448*Women with BCWomen without BC*Any cause: 39.3Any cause: 16.7Women without BC; 3,554,255^h^ICD-10: I20, I21--I22, I23--I25, I30--I50, I52, I60--I79CVD: 10.4CVD: 7.5BC: 18.1BC: -CVD mortality in breast cancer patients by patient, tumor, and treatment characteristicsColzani, 2011, Sweden^a^Primary invasive I-III; 12,850\<751990--2006, 10^e^ICD-9: 390--459Any cause:14.4ICD-10: I00--I99CVD:1.8BC:9.2Hooning, 2006, the Netherlands^f^Primary invasive I-IIIA; 7425≤701970--1986, 13.8^b^ICD-9: 410--459Any cause:56.0CVD:5.3BC:42.6CVD mortality in patients with left-sided breast cancer compared to right-sided breast cancerBouchardy, 2009, Switzerland^a^Primary invasive lymph node-negative; 124557.4^d^1980--2004, 7.7^d^ICD-10: I00-I99Any cause:12.4CVD:2.2BC:7.3Darby, 2005, US^a^Primary in situ or invasive; 308,86120--791973--2001, 29^e^ICD-9: 390--398, 402, 404, 410, 411--414, 415--429Any cause:29.5CVD:4.2BC:16.8Giordano, 2005, US^a^Primary in situ or invasive; 24,78556.9 ± 13.2^d^1973--1988, 9.3^b^ICD-9: 410-414Any cause:--ICD-10: I20--I25CVD:--BC:--Haque, 2017, US^a^DCIS, 140,914≤60 & \>601973--2002, 11.5--Any cause:--(IQR: 6.8--15.1)^b^CVD:--BC:--Merzenich, 2016, Germany^g^Primary in situ or invasive; 11,98259^d^1998--2008, 6.5 (0--15)^b^ICD-10: I20--I25, I34--I37, I44--I50Any cause:20.6(range: 18--101)CVD:2.3BC:10.2CVD mortality in breast cancer patient with ethnic differencesBerkman, 2014, US^a^Primary DCIS; 54,518 white women; 6113 black women≥401978--2010, 9.2^b^ICD-10: I00--I09, I11, I13, I20--I51, I60--I69, I70, I72--178Any cause:18.0CVD:6.0BC:1.5Solanki, 2016, US^a^Primary in situ or invasive I-III; 462,005 NHW; 44,531 APINHW: 61.2 ± 13.7^d^1991--2011,ICD-9: 390--459*Non-Hispanic whiteAsian and Pacific Islander*API: 56.3 ± 13.1^d^NHW: 6.8 ± 4.9^d^,Any cause: 23.8Any cause: 15.44 (2--6) ^b^CVD: 5.5CVD: 2.6API: 6.7 ± 5.0^d^,BC: 10.0BC: 8.23 (2--5)^b^CVD mortality in breast cancer patients by diet, body weight, and health behaviorsMcCullough, 2016, Switzerland^g^Primary invasive I-III; 4452 for pre-diagnostic of which 2152 were included in the ≥1-year post- diagnostic analysis70.7 ± 7.2^d^1992--2011, pre-diagnostic diet assessment 9.8 ± 4.9, post-diagnostic analyses 9.9 ± 3.3^d^ICD-9: 390-459Any cause:27.0ICD-10: I00-I99CVD:5.2BC:8.9Nichols, 2009, US^a^Primary in situ or invasive; 579158.4 ± 10.0^d^1988--1999, 6.4 ± 1.2^d^ICD-10: I00-99Any cause:7.3CVD:1.6BC:2.1Veal, 2017, US^g^Primary DCIS; 192520--741997--2006, 6.7^d^ICD-10: I00-I09, I11, I13, I20-I51, I60-I69, I70, I72-I78Any cause:10.2CVD:1.8BC:4.5*BC* breast cancer, *CVD* cardiovascular disease, *DCIS* ductal carcinoma in situ, *ICD-9* International Classification of Diseases version 9, *ICD-10* International Classification of Diseases version 10, *y* years, *US*  United States of America^a^Population-based registry^b^Median with (range if described by the article)^c^Women without breast cancer were matched on age and the expected distribution of survivors in 5-year age groups with women with breast cancer^d^Mean with (±standard deviation if described by the article)^e^Maximum^f^Hospital-based registry^g^Prospective cohort study^h^All women who were born before 1977 who resided in Sweden were included; women without breast cancer were part of the reference group Table 3Risk factors of death from cardiovascular disease in women diagnosed with breast cancerFirst author, year of publicationStatistical analysisCategoriesCause of death (outcome)Risk of death HR (95% CI)CovariatesCVD mortality in breast cancer patients compared with the general populationBradshaw, 2016Competing riskGeneral populationCVD1.0 (ref)Age, menopausal status, CVD risk factorsBreast cancer patients diagnosed 0--7 years ago0.59 (0.4--0.9)General populationCVD1.00 (ref)Breast cancer patients diagnosed \>7 years ago1.9 (1.4--2.7)General populationCVD1.0 (ref)Breast cancer patients treated with RT1.1 (0.8--1.6)General populationCVD1.0 (ref)Breast cancer patients treated without RT1.3 (0.9--2.0)General populationCVD1.0 (ref)Breast cancer patients treated with CT1.4 (1.0--2.2)General populationCVD1.0 (ref)Breast cancer patients treated without CT1.1 (0.8--1.5)General populationCVD1.0 (ref)Breast cancer patients treated with HT1.2 (0.9--1.7)General populationCVD1.0 (ref)Breast cancer patients treated without HT1.2 (0.8--1.8)Riihimäki, 2012Cox proportional hazardGeneral populationCVA1.00 (ref)Age, socioeconomic index, geographical region of residenceBreast cancer patients1.03 (1.00--1.07)General populationAMI1.00 (ref)Breast cancer patients1.01 (0.98--1.0)General populationOther CHD1.00 (ref)Breast cancer patients1.14 (1.10--1.19)General populationHeart failure1.00 (ref)Breast cancer patients1.29 (1.22--1.37)General populationOther heart disease1.00 (ref)Breast cancer patients1.24 (1.17--1.32)General populationArterial disease1.00 (ref)Breast cancer patients0.95 (0.89--1.02)General populationComplications of CVD1.00 (ref)Breast cancer patients1.12 (0.99--1.2)CVD mortality in breast cancer patients by patient, tumor, and treatment characteristicsColzani, 2011Flexible parametric survival modelsAge at diagnosis\<45CVD0.3 (0.0--2.5)Clinical, tumor, treatment characteristics45--541.00 (ref)55--646.5 (2.8--14.6)65--7417.9 (8.0--39.7)Calendar time at diagnosis1990--1994CVD2.1 (1.2--3.6)1995--19991.6 (0.9--2.9)2000--20061.00 (ref)TreatmentSurgeryCVD2.1 (1.2--3.8)Surgery + RT + HT1.00 (ref)Surgery + RT1.4 (0.7--2.5)Surgery + RT + CT0.6 (0.1--2.5)Surgery + CT2.0 (0.6--6.8)Surgery + RT + CT + HT0.7 (0.3--1.9)Surgery + HT2.2 (1.5--3.2)Surgery + CT + HT1.0 (0.2--4.5)No. of positive lymph nodes0CVD1.00 (ref)1--32.0 (1.4--2.9)≥4(1.0-3.4)Estrogen receptorNegativeCVD1.00 (ref)StatusPositive0.8 (0.5--1.3)Tumor size in mm1--20CVD1.00 (ref)\>201.5 (1.1--2.1)Hooning, 2006Cox proportional hazard*Total study population*Clinical, tumor, treatment, characteristicsAge at diagnosis (continuous)CVD1.12 (1.10--1.14)TreatmentSurgeryCVD1.00 (ref)Surgery + RT2.03 (1.33--3.10)Surgery + RT + CT1.47 (0.81--2.67)Surgery + RT + HT1.70 (0.99--2.93)Calendar time at diagnosis1970--1975CVD1.34 (0.93--1.92)1976--19801.54 (1.11--2.14)1981--861.00 (ref)*10-year survivors*Age at diagnosis (continuous)CVD1.11 (1.09--1.13)TreatmentSurgeryCVD1.00 (ref)Surgery + RT2.08 (1.25--3.47)Surgery + RT + CT2.38 (1.18--4.77)Surgery + RT + HT2.42 (1.27--4.61)Calendar time at diagnosis1970--1975CVD1.38 (0.89--2.14)1976--19801.62 (1.07--2.46)1981--19861.00 (ref)CVD mortality in breast cancer patients by laterality of the tumorBouchardy, 2016Cox proportional hazardRT and right-sided tumorCVD1.00 (ref)Clinical, tumor, and treatment characteristicsRT and left-sided tumor0.52 (0.24--1.12)RT and outer quadrantCVD1.00 (ref)RT and inner quadrant2.46 (1.13--5.37)RT and right-sided tumor and outer quadrantCVD1.00 (ref)RT and right-sided tumor and inner quadrant2.51 (0.88--7.18)RT and left-sided tumor and outer quadrantCVD1.00 (ref)RT and left-sided tumor and inner quadrant2.17 (0.65--7.25)RT and outer quadrant and right-sided tumorCVD1.00 (ref)RT and outer quadrant and left-sided tumor0.70 (0.21--2.32)RT and inner quadrant and right-sided tumorCVD1.00 (ref)RT and inner quadrant and left-sided tumor0.52 (0.18-1.48)Darby, 2005Poisson regression for mortality ratesRT on right-sided tumorCVD1.00 (ref)No covariatesRT on left-sided tumor1.44 (1.26--1.65)RT on right-sided tumorAMI1.00 (ref)RT on left-sided tumor1.43 (1.10--1.87)RT on right-sided tumorOther1.00 (ref)IschemicCVDRT on left-sided tumor1.60 (1.26--2.02)RT on right-sided tumor and aged 20--49 years at diagnosisCVD1.00 (ref)RT on left-sided tumor and aged 20--49 years at diagnosis1.54 (1.08--2.19)RT on right-sided tumor and aged 50--59 years at diagnosisCVD1.00 (ref)RT on left-sided tumor and aged 50--59 years at diagnosis1.53 (1.19--1.98)RT on right-sided tumor and aged 60--69 years at diagnosisCVD1.00 (ref)RT on left-sided tumor and aged 60--69 years at diagnosis1.40 (1.15--1.70)RT on right-sided tumor and aged 70--79 years at diagnosisCVD1.00 (ref)RT on left-sided tumor and aged 70--79 years at diagnosis1.28 (0.87--1.90)RT on right-sided tumor and white ethnic originCVD1.00 (ref)RT on left-sided tumor and white ethnic origin1.39 (1.21--1.61)RT on right-sided tumor and black ethnic originCVD1.00 (ref)RT on left-sided tumor and black ethnic origin2.25 (1.36--3.72)RT on right-sided tumor and other/ unknown ethnic originCVD1.00 (ref)RT on left-sided tumor and other/ unknown ethnic origin1.30 (0.71--2.39)Giordano, 2005Cox proportional hazardRight-sided tumor and diagnosed in 1979CVD1.00 (ref)No covariatesLeft-sided tumor and diagnosed in 19791.50 (1.19--1.87)Right-sided tumor and diagnosed in 1988CVD1.00 (ref)Left-sided tumor and diagnosed in 19880.79 (0.52--1.18)Haque, 2016Cox proportional hazard*Diagnosed 1973--1982*Clinical, tumor, treatment characteristicsRight-sided tumorCVD1.00 (ref)Left-sided tumor1.30 (1.18--1.42)RaceWhiteCVD1.00 (ref)African American1.14 (0.94--1.36)American Indian/0.83 (0.66--1.02)Asian/ PacificIslanderUnspecified0.47 (0.03--2.06)Age at diagnosis≤60CVD1.00 (ref)\>605.87 (5.30--6.50)Marital statusMarriedCVD1.00 (ref)Unmarried1.87 (1.70--2.05)Unknown1.77 (1.29--2.37)Right-sided tumor and \<10 years since diagnosisCVD1.00 (ref)Left-sided tumor and \<10 years since diagnosis1.14 (0.99--1.32)Right-sided tumor and 10--19 years since diagnosisCVD1.00 (ref)Left-sided tumor and 10--19 years since diagnosis1.32 (1.12--1.57)Right-sided tumor and ≥20 years since diagnosisCVD1.00 (ref)Left-sided tumor and ≥20 years since diagnosis1.30 (1.10--1.54)RegionPacificCVD1.00 (ref)Alaska--East0.97 (0.86-1.09)Northern Plains1.35 (1.21-1.51)Southwest1.51 (0.98-1.34)*Diagnosed 1983--1992*Right-sided tumorCVD1.00 (ref)Left-sided tumor1.02 (0.95--1.10)RaceWhiteCVD1.00 (ref)African American1.14 (0.98--1.32)American Indian/0.68 (0.56--0.82)Asian/ PacificIslanderUnspecified0.39 (0.02--1.74)Age at diagnosis≤60CVD1.00 (ref)\>6010.16 (9.62--11.30)Marital statusMarriedCVD1.00 (ref)Unmarried2.25 (2.08--2.42)Unknown1.65 (1.28--2.08)Right-sided tumor and \<10 years since diagnosisCVD1.00 (ref)Left-sided tumor and \<10 years since diagnosis1.01 (0.90--1.13)Right-sided tumor and 10--19 years since diagnosisCVD1.00 (ref)Left-sided tumor and 10--19 years since diagnosis0.98 (0.88--1.10)Right-sided tumor and ≥ 20 years since diagnosisCVD1.00 (ref)Left-sided tumor and ≥20 years since diagnosis0.94 (0.77--1.15)RegionPacificCVD1.00 (ref)Alaska0.00 (0.00--14.13)East1.09 (0.99--1.20)Northern Plains1.42 (1.30--1.56)Southwest1.13 (0.97--1.30)*Diagnosed 1993--1902*Right-sided tumorCVD1.00 (ref)Left-sided tumor0.99 (0.93--1.05)RaceWhiteCVD1.00 (ref)African American1.32 (1.20--1.45)American Indian/0.53 (0.46--0.61)Asian/ PacificIslanderUnspecified0.11 (0.01--0.47)Age at diagnosis≤60CVD1.00 (ref)\>6010.73 (9.86--11.70)Marital statusMarriedCVD1.00 (ref)Unmarried2.21 (2.28--2.55)Unknown1.90 (1.60--2.24)Right-sided tumor and \<10 years since diagnosisCVD1.00 (ref)Left-sided tumor and \<10 years since diagnosis1.00 (0.98--1.03)Right-sided tumor and ≥20 years since diagnosisCVD1.00 (ref)Left-sided tumor and ≥20 years since diagnosis1.01 (0.91--1.11)RegionPacificCVD1.00 (ref)Alaska0.24 (0.01--1.07)East1.06 (0.99--1.13)Northern Plains1.25 (1.16--1.35)Southwest0.87 (0.76--0.99)Merzenich, 2016Cox proportional hazardRT and right-sided tumorCVD1.0 (ref)Clinical, tumor, treatment characteristicsRT and left-sided tumor0.94 (0.64--1.38)No RT and right-sided tumorCVD1.0 (ref)No RT and left-sided tumor1.07 (0.79--1.46)RT without a history of cardiac diseaseCVD1.0 (ref)RT with a history of cardiac disease1.73 (1.11--2.68)RT without chemotherapyCVD1.0 (ref)RT with chemotherapy0.66 (0.37--1.19)CVD mortality in breast cancer patients with different ethnic originsBerkman, 2014Kaplan-- Meier\
with log-rank statisticsWhite and diagnosed between 1990 and 2010CVD1.00 (ref)No covariatesBlack and diagnosed between 1990 and 20106.43 (3.61--11.45)White and age at diagnosis 40--49 yearsCVD1.00 (ref)Black and age at diagnosis 40--49 years9.83 (4.56--21.17)White and age at diagnosis 50--59 yearsCVD1.00 (ref)Black and age at diagnosis 50--59 years3.35 (2.14--5.24)White and age at diagnosis 60--69 yearsCVD1.00 (ref)Black and age at diagnosis 60--69 years2.13 (1.65--2.74)White and age at diagnosis ≥70 yearsCVD1.00 (ref)Black and age at diagnosis ≥70 years1.07 (0.93--1.23)Solanki, 2016Cox proportional hazardNon-Hispanic whiteCVD1.00 (ref)Age, birthplace, SEER registry, AJCC stageAsian and Pacific islander0.77 (0.71--0.83)Non-Hispanic whiteCVD1.00 (ref)Chinese0.66 (0.56--0.78)Non-Hispanic whiteCVD1.00 (ref)Japanese0.71 (0.62--0.81)Non-Hispanic whiteCVD1.00 (ref)Filipino0.90 (0.78--1.03)Non-Hispanic whiteCVD1.00 (ref)Hawaiian1.43 (1.17--1.75)Non-Hispanic whiteCVD1.00 (ref)Korean0.68 (0.46--0.99)Non-Hispanic whiteCVD1.00 (ref)Vietnamese0.46 (0.28--0.76)Non-Hispanic whiteCVD1.00 (ref)Asian Indian and Pakistani0.98 (0.70--1.37)Non-Hispanic whiteCVD1.00 (ref)Pacific Islander1.33 (0.83--2.15)Non-Hispanic whiteCVD1.00 (ref)Other Asian0.61 (0.45--0.83)Non-U.S. born Asian and Pacific IslanderCVD1.00 (ref)U.S. born Asian and Pacific Islander1.29 (1.08--1.54)Non-U.S. born ChineseCVD1.00 (ref)U.S. born Chinese1.33 (0.81--2.20)Non-U.S. born JapaneseCVD1.00 (ref)U.S. born Japanese1.04 (0.74--1.48)Non-U.S. born FilipinoCVD1.00 (ref)U.S. born Filipino0.99 (0.57--1.72)Non-U.S. born HawaiianCVD1.00 (ref)U.S. born Hawaiian0.97 (0.13--7.38)Non-U.S. born KoreanCVD1.00 (ref)U.S. born Korean0.17 (0.02--1.69)Non-U.S. born Asian Indian and PakistaniCVD1.00 (ref)U.S. born Asian Indian and Pakistani0.94 (0.11--8.13)Non-U.S. born Pacific IslanderCVD1.00 (ref)U.S. born Pacific Islander4.27 (0.68--26.7)Non-U.S. born Other AsianCVD1.00 (ref)U.S. born Other Asian2.06 (0.84--5.10)CVD mortality in breast cancer patients by diet, body weight, and health behaviorsMcCullough, 2016Cox proportional hazardPre-diagnostic diet score (continuous)CVD0.96 (0.84--1.10)Clinical, tumor, and treatment characteristics, CVD risk factorsPre-diagnostic diet score 0--2CVD1.00 (ref)Pre-diagnostic diet score 3--50.95 (0.68--1.32)Pre-diagnostic diet score 6--90.94 (0.63--1.39)Post-diagnostic diet score (continuous)CVD0.95 (0.79--1.14)Post-diagnostic diet score 0--2CVD1.00 (ref)Post-diagnostic diet score 3--50.96 (0.60--1.54)Post-diagnostic diet score 6--90.81 (0.47--1.39)Nichols, 2009Cox proportional hazardOne to 5 year before diagnosis a BMI \<18.5CVD4.15 (1.44--12.0)Age, menopausal status, and other CVD risk factorsOne to 5 year before diagnosis a BMI 18.5−24.91.00 (ref)One to 5 year before diagnosis a BMI 25.0−29.91.05 (0.63--1.74)One to 5 year before diagnosis a BMI ≥302.45 (1.46--4.11)BMI after diagnosis \<18.5CVD0.58 (0.08--4.34)BMI after diagnosis 18.5−24.91.00 (ref)BMI after diagnosis 25.0−29.90.99 (0.59--1.66)BMI after diagnosis ≥301.65 (0.97--2.83)Weight (kg) change −50.0 to −10.1CVD1.08 (0.42--2.78)Weight (kg) change −10.0 to −2.11.02 (0.58--1.80)Weight (kg) change −2.0 to 2.01.00 (ref)Weight (kg) change 2.1--6.00.79 (0.43--1.44)Weight (kg) change 6.1--10.00.64 (0.29--1.44)Weight (kg) change 10.11.73 (0.83--3.62)Veal, 2017Cox proportional hazard*Pre-diagnosis behaviors*Demographic, clinical, tumor, and treatment characteristicsBMIContinuousCVD1.01 (0.95--1.07)18.5--24.9CVD1.0 (ref)25.0--29.90.88 (0.37--2.07)30.0--34.91.21 (0.45--3.24)≥35.01.85 (0.59--5.85)Physical activity (hours per week)ContinuousCVD0.83 (0.70--0.98)No activityCVD1.0 (ref)0--1.90.52 (0.22--1.23)2.0--4.90.38 (0.15--1.00)≥5.00.29 (0.08--1.04)Alcohol (drinks per week)ContinuousCVD1.01 (0.94--1.08)Non-drinkerCVD1.0 (ref)0--1.90.68 (0.29--1.60)2.0--6.91.22 (0.47--3.14)≥7.00.49 (0.13--1.86)SmokingNon-smokerCVD1.0 (ref)Former smoker0.96 (0.43--2.15)Current smoker2.07 (0.84--5.11)*Post-diagnosis behaviors*Pre-diagnosis health behavior and demographic, clinical, tumor, and treatment characteristicsBMIContinuousCVD0.96 (0.85--1.08)18.5--24.9CVD1.0 (ref)25.0--29.90.90 (0.32--2.51)30.0--34.90.63 (0.15--2.70)≥35.00.36 (0.05--2.74)Physical activity (hours per week)ContinuousCVD1.04 (0.91--1.18)No activityCVD1.0 (ref)0--1.90.35 (0.04--2.97)2.0--4.90.42 (0.05--3.60)≥5.02.27 (0.40--12.76)Alcohol (drinks per week)ContinuousCVD0.90 (0.67--1.22)Non-drinkerCVD1.0 (ref)0--1.91.43 (0.37--5.62)2.0--6.91.53 (0.24--9.89)≥7.00.57 (0.04--8.52)SmokingNon-smokerCVD1.0 (ref)Former smoker0.92 (0.41--2.08)Current smoker1.27 (0.22--6.86)*AJCC* American Joint Committee on Cancer, *AMI* acute myocardial infarction, *BMI* body mass index; kg/m^2^, *CHD* Coronary heart disease, *CI* confidence interval, *CT* chemotherapy, *CVA* cerebrovascular accident, *CVD* cardiovascular disease, *DCIS* ductal carcinoma in situ, *HR* hazard ratio, *HT* hormonal therapy, *MR* mortality ratio, *ref* reference category, *RT* radiotherapy, *SD* standard deviation, *SEER* Surveillance, Epidemiology, and End Results, *US* United States

Riihimäki et al. \[[@CR5]\] included all 3,676,472 female Swedish residents born before 1977 (Table [2](#Tab2){ref-type="table"}). Of these, 122,217 were diagnosed with primary invasive breast cancer between 1987 and 2006. During a maximum follow-up of 19 years, 10.4% and 7.5% of women died of CVD, respectively. Women with breast cancer had a 1.14 (95% CI 1.10--1.19) times higher risk to die of coronary heart disease, a 1.29 (95% CI 1.22--1.37) times higher risk to die of heart failure, and a 1.24 (95% CI 1.17--1.32) times higher risk to die of other heart disease than women from the general population, independent of age, socioeconomic index, and geographical region of residence in Sweden (Table [3](#Tab3){ref-type="table"}).

Cardiovascular disease mortality in breast cancer patients by patient, tumor, and treatment characteristics {#Sec8}
-----------------------------------------------------------------------------------------------------------

Colzani et al. \[[@CR18]\] included 12,850 Swedish women younger than 75 years of age at diagnosis with primary invasive stage I to III breast cancer between 1990 and 2006 (Table [2](#Tab2){ref-type="table"}). During a maximum follow-up of ten years, 1.8% of all women died of CVD. After adjusting for clinical, tumor, and treatment characteristics, except the one of interest, women with breast cancer were at increased risk of CVD mortality if they were older at diagnosis (65--74 years vs. 45--54 years: hazard ratio (HR) = 17.9, 95% CI 8.0--39.7), if diagnosed in an earlier calendar period (1990--1994 vs. 2000--2006: HR = 2.1, 95% CI 1.2--3.6), and treated with only surgery (HR = 2.1, 95% CI 1.2--3.8) or surgery in combination with hormonal therapy (HR = 2.2, 95% CI 1.5--3.2) compared with surgery in combination with radiotherapy and hormonal therapy (Table [3](#Tab3){ref-type="table"}).

Hooning et al. \[[@CR25]\] included 7425 women younger than 71 years of age at diagnosis with primary invasive stage I to IIIA breast cancer in the Netherlands between 1970 and 1986 (Table [2](#Tab2){ref-type="table"}). During a median follow-up of 13.8 years, 5.3% of all women died of CVD. After adjusting for clinical, tumor, and treatment characteristics, women with breast cancer were at increased risk of CVD mortality with each year increase in age at diagnosis (HR = 1.12, 95% CI 1.10--1.14), if diagnosed in an earlier calendar period (1976--1980 vs. 1981--1986: HR = 1.54, 95% CI 1.11--2.14), and treated with a combination of surgery and radiotherapy compared with only surgery (HR = 2.03, 95% CI 1.33--3.10) (Table [3](#Tab3){ref-type="table"}).

Cardiovascular disease mortality in breast cancer patients by laterality of the tumor {#Sec9}
-------------------------------------------------------------------------------------

Bouchardy et al. \[[@CR20]\] included 1245 women with a mean age of 57.4 years at diagnosis with primary lymph node-negative breast cancer in Switzerland between 1980 and 2004 (Table [2](#Tab2){ref-type="table"}). During a mean follow-up of 7.7 years, 2.2% of all women died of CVD. Among women treated with radiotherapy, an inner quadrant tumor was associated with a 2.46 (95% CI 1.13--5.37) higher risk of dying of CVD, adjusted for clinical, tumor, and treatment characteristics (Table [3](#Tab3){ref-type="table"}).

Darby et al. \[[@CR23]\] included 308,861 women between 20 and 79 years of age at diagnosis with primary in situ or invasive breast cancer in the USA between 1973 and 2001 (Table [2](#Tab2){ref-type="table"}). During a maximum follow-up of 29 years, 4.2% of all women died of CVD. In women treated with radiotherapy and diagnosed between 1973 and 1982, left-sided breast cancer led to higher mortality ratios (MR) ten to 14 years post diagnosis (unadjusted MR = 1.42, 95% CI 1.11--1.82) and over 15 years post diagnosis (unadjusted MR = 1.58, 95% CI 1.29--1.95) compared with right-sided breast cancer (Table [3](#Tab3){ref-type="table"}). More than ten years post diagnosis, women with left-sided breast cancer had a higher risk of death from CVD (unadjusted MR = 1.44, 95% CI 1.26--1.65), acute myocardial infarction (unadjusted MR = 1.43, 95% CI 1.10--1.87), and other ischemic CVD (unadjusted MR = 1.60, 95% CI 1.26--2.02) compared with women with right-sided breast cancer.

Giordano et al. \[[@CR24]\] included 24,785 women with primary in situ or invasive breast cancer diagnosed in the US between 1973 and 1988 (Table [2](#Tab2){ref-type="table"}). Mean age at diagnosis was 56.9 years (standard deviation (SD) = 13.2) at diagnosis. Eight years post diagnosis, women with left-sided breast cancer who were diagnosed in 1979 had a (unadjusted) 1.50 (95% CI 1.15--1.87) times higher risk to die of CVD compared with women with right-sided breast cancer diagnosed in the same year (Table [3](#Tab3){ref-type="table"}).

Haque et al. \[[@CR26]\] included 140,914 women of all ages with ductal carcinoma in situ (DCIS) in the US between 1973 and 2002 (Table [2](#Tab2){ref-type="table"}).The median follow-up was 11.5 years (interquartile range = 6.8--15.1). Among women diagnosed between 1973 and 1982, a left-sided tumor was associated with a 1.30 (95% CI 1.18--1.42) higher risk of dying of CVD than a right-sided tumor, independent of clinical, tumor, and treatment characteristics. This association was not found for women diagnosed in a more recent calendar period.

Merzenich et al. \[[@CR21]\] included 11,982 women with a mean age of 59 years (range = 18--101) at primary diagnosis of in situ or invasive breast cancer in Germany between 1998 and 2008 (Table [2](#Tab2){ref-type="table"}) \[[@CR21]\]. During a median follow-up of 6.5 years (range = 0--15), 2.3% of all women died of CVD. Women with left-sided breast cancer did not have a higher risk of dying of CVD than women with right-sided breast cancer, irrespectively of radiotherapy treatment (Table [3](#Tab3){ref-type="table"}). Among women treated with radiotherapy, women with a history of CVD had a 1.73 times (95% CI 1.11--2.68) higher risk of dying of CVD than women without a history of CVD.

CVD mortality in breast cancer patient by ethnic origin {#Sec10}
-------------------------------------------------------

Berkman et al. \[[@CR6]\] included 54,518 white and 6113 black women over 40 years of age at diagnosis with primary DCIS in the US between 1978 and 2010 (Table [2](#Tab2){ref-type="table"}). During a median follow-up of 9.2 years, 6.0% of all women died of CVD. Among women diagnosed with breast cancer between 1990 and 2010, black women had a (unadjusted) 6.43 (95% CI 3.61--11.45) times higher risk of death from CVD compared to white women (Table [3](#Tab3){ref-type="table"}). Unadjusted HRs of CVD death in black compared to white women decreased with increasing age at diagnosis: 9.83 (95% CI 4.56--21.17), 3.35 (95% CI 2.14--5.24), 2.13 (95% CI 1.65--2.74), and 1.07 (95% CI 0.93--1.23) for women of ages 40--49, 50--59, 60--69, and ≥ 70 years, respectively.

Solanki et al. \[[@CR17]\] included 462,005 non-Hispanic white and 44,531 Asian and Pacific Islander women diagnosed with breast cancer in the US between 1991 and 2001 (Table [2](#Tab2){ref-type="table"}). Median age at breast cancer diagnosis was 61.2 years (SD = 13.7) for non-Hispanic white women and 56.3 years (SD = 13.1) for Asian and Pacific Islander women. The median follow-up for non-Hispanic white women was 4 years (range = 2-6), during which 5.5% of women died of CVD. The median follow-up for Asian and Pacific Islander women was 3 years (range 2--5), during which 2.6% of women died of CVD. After adjusting for patient, tumor, and registry characteristics, Asian and Pacific Islander women with breast cancer had a HR of 0.77 (95% CI 0.71--0.83) for death from CVD compared to non-Hispanic white women with breast cancer (Table [2](#Tab2){ref-type="table"}). Furthermore, US born Asian and Pacific Islander women with breast cancer had a 1.29 (95% CI 1.08--1.54) times higher risk of death from CVD compared to non-US born Asian and Pacific Islander women with breast cancer.

CVD mortality in breast cancer patients by diet, body weight, and health-behaviors {#Sec11}
----------------------------------------------------------------------------------

McCullough et al. \[[@CR16]\] included 4452 women diagnosed with primary invasive breast cancer in Switzerland between 1992 and 2011 who had scored their diet according to the American Cancer Society (AMC) guidelines before breast cancer diagnosis, and of these, 2152 women scored their diet also at least one year after breast cancer diagnosis (Table [2](#Tab2){ref-type="table"}). The AMC guidelines recommend following the general food-based guidelines for primary cancer prevention, which includes eating a plant-based diet rich in vegetables and fruits, whole grains, and which is limited in red and processed meats \[[@CR27]\]. Mean age at diagnosis was 70.7 years (SD = 7.2). During a mean follow-up of 9.8 years (SD = 4.9), 5.2% of all women died of CVD. After adjusting for tumor, treatment, and patient characteristics, both pre-diagnostic and post-diagnostic higher AMC diet scores, indicating an unhealthier diet, were not associated with a higher risk of CVD mortality following breast cancer compared with the lowest diet score category (0--2), indicating a healthier diet (Table [3](#Tab3){ref-type="table"}).

Nichols et al. \[[@CR15]\] included 5791 women with primary in situ or invasive breast cancer diagnosed in the US between 1988 and 1999 (Table [2](#Tab2){ref-type="table"}). Mean age at diagnosis was 58.4 years (SD = 10.0). During a mean follow-up of 6.4 years (SD = 1.2), 1.6% of all women died of CVD. After correcting for age, menopausal status, and CVD risk factors, Nichols et al. found a 4.15 (95% CI 1.44--12.0) and 2.45 (95% CI 1.46--4.11) times higher risk of death from CVD in women with a pre-diagnosis underweight (body mass index (BMI; kg/m^2^): \<18.5) and obesity (BMI: ≥ 30), respectively, compared with women with a pre-diagnosis normal weight (BMI: 18.5--24.9) (Table [3](#Tab3){ref-type="table"}).

Veal et al. \[[@CR22]\] included 1925 women aged between 20 and 74 years at diagnosis of DCIS in the US between 1997 and 2006 (Table [2](#Tab2){ref-type="table"}). During a mean follow-up of 6.7 years, 1.8% of all women died of CVD. More hours per week of physical activity before the breast cancer diagnosis was associated with 0.83 (95% CI 0.70--0.98) lower risk of dying of CVD (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec12}
==========

In this review, we systematically summarized the evidence on the risk and risk factors of death from CVD following breast cancer.

The absolute risk of dying of CVD following breast cancer ranges from 1.6% \[[@CR15]\] to 10.4% \[[@CR5]\], and the risk of CVD mortality is higher in women with breast cancer than women from the general population \[[@CR5], [@CR8]\]. Older age at diagnosis \[[@CR6], [@CR18], [@CR19], [@CR25]\], left-sided tumor \[[@CR23], [@CR24], [@CR26]\], diagnosis in an earlier calendar period \[[@CR18], [@CR25]\], and black ethnic origin \[[@CR6]\] are risk factors of CVD mortality following breast cancer.

Several mechanisms are proposed for the increased risk of CVD mortality in women with breast cancer. CVD risk factors, such as obesity and diabetes, may be more present among breast cancer survivors than women from the general population as breast cancer and CVD have shared risk factors \[[@CR28]\]. Also, cardiotoxic effects of breast cancer treatments, specifically mediastinal and left-sided radiotherapy, anthracycline-based chemotherapy, and trastuzumab, are well documented to increase the risk of CVD \[[@CR29]--[@CR32]\].

In the current review, studies with longer follow-up, i.e. over 10 years \[[@CR5], [@CR6], [@CR8]\], reported higher absolute risks of CVD mortality. The risk of CVD increases with time since diagnosis probably due to increasing age and cardiotoxicity of breast cancer treatments that become apparent after several years \[[@CR29]\]. Age is a well-known risk factor for CVD \[[@CR33]--[@CR36]\], and therefore, expected to be found as a risk factor in women with breast cancer \[[@CR6], [@CR18], [@CR19], [@CR25]\]. Schonberg et al. \[[@CR14]\] found that 26--40% of older women diagnosed with early-stage breast cancer died of CVD, indicating that the risk of CVD is high in specific subgroups and particularly in older women.

The association between left-sided breast cancer and radiotherapy treatment with a higher risk of CVD mortality was found among women diagnosed in the early 1980's \[[@CR23], [@CR24], [@CR26]\]. Radiotherapy treatment was more cardiotoxic in these years as it usually involved higher doses with large irradiation fields irradiating parts of the heart \[[@CR37], [@CR38]\]. This may also explain the increased risk of CVD mortality among breast cancer patients diagnosed in an earlier calendar period \[[@CR18], [@CR25]\]. Colzani et al. \[[@CR18]\] did not find an increased risk of CVD mortality among women treated with radiotherapy and/or chemotherapy. Although the baseline risk of CVD was not reported, this result is probably due to patient selection, i.e. women who did not undergo radiotherapy and/or chemotherapy probably had a higher risk of CVD at baseline. The lower risk of CVD in Asian populations \[[@CR17]\] and the higher risk of CVD in black populations \[[@CR6]\] are reported by several studies and can be explained by the lower and higher presence of CVD risk factors, respectively, such as high blood pressure, obesity, and lipid levels \[[@CR39]--[@CR42]\].

The present systematic review shows that there are only a limited number of studies investigating the risk and risk factors of CVD mortality following breast cancer, and that these studies are heterogeneous in design, study population, and length of follow-up. Also, the determinants and outcomes, in terms of CVD risk factors and death due to CVD, respectively, vary. We acknowledge that, due to the heterogeneous designs of the included studies, we were unable to perform a meta-analysis, which limited the strength of evidence. Besides limitations, the current review has strengths. This is the first study that systematically summarized the literature on the risk and risk factors of death from CVD following breast cancer. Furthermore, the current systematic review includes a large variety of risk factors of death from CVD in women with breast cancer.

To conclude, the combination of high breast cancer incidence, improved breast cancer survival, presence of CVD risk factors, and cardiotoxic breast cancer treatments has resulted into many breast cancer survivors at risk of CVD. Therefore, it is important to understand the incidence and etiology of CVD in these survivors. Furthermore, identification of women with breast cancer at high risk of CVD is important to minimize the number of women suffering and/or dying of CVD after breast cancer treatment and improve quality of life and long-term prognosis. Clinicians should be able to identify breast cancer patients at increased risk of CVD and provide accurate recommendations for CVD risk reduction strategies specifically for breast cancer survivors at high risk of CVD. The current systematic review, in combination with a recent guideline by Armenian et al. \[[@CR29]\] on the prevention and monitoring of cardiac dysfunction in survivors of adult cancers, may help clinicians with such a recommendation. In addition, there are studies investigating the identification of women with breast cancer at high risk of CVD using other measurements, for example, by measuring the coronary artery calcification on radiotherapy planning computed tomography scans \[[@CR43]\]. This may further help clinicians with identification of breast cancer patients at high risk of CVD. Identification of breast cancer patients at high risk of CVD is important to optimize CVD prevention of (irreversible) cardiac damage, by adjusting breast cancer treatments accordingly and initializing CVD (preventative) treatment. Furthermore, a tailored individual approach with early and late monitoring of cardiac dysfunction in breast cancer survivors should be implemented in routine care \[[@CR44]\].
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